BlueRun Ventures
BlueRun Ventures (蓝驰创投) is a Beijing-headquartered early-stage venture capital firm managing 15B+ RMB across 200+ Chinese technology, consumer, and healthcare startups, with deep recent focus on AI and embodied intelligence including Moonshot AI, Zhiyuan Robotics, and Galbot.
- Company typePrivate
- Founded2005
- HeadquartersChaoyang, China
- Headcount—
- GTM typeB2B
- OfferingServices
What BlueRun Ventures does
BlueRun Ventures (蓝驰创投) is a China-focused early-stage venture capital firm founded in 2005, headquartered in Beijing with operational presence in Shanghai, Shenzhen, and Hong Kong. The firm manages over 15 billion RMB (~150亿) in long-cycle capital and has invested in more than 200 portfolio companies across technology, consumer, and healthcare sectors, with notable exits including Li Auto (NASDAQ/HKEx 2021), WaterDrop (NYSE 2021), QingCloud (STAR Market 2021), and Monster Charge (NASDAQ 2021). It leads 80% of its deals, often at seed stage, and consistently follows on across subsequent rounds—evidenced by five consecutive rounds in Li Auto from A2 through C and three successive rounds in Zhiyuan Robotics.
The firm is managed by Managing Partners Chen Weiguang (陈维广), Zhu Tianyu (朱天宇), and Cao Wei (曹巍), supported by Partner Liu Ji (刘吉). The team is structured around scientist/PhD backgrounds and former industry operators, providing technical due-diligence capability for deep-tech bets. Since 2024, BlueRun has materially concentrated its thesis on AI and embodied intelligence, leading rounds in humanoid robotics (Galbot/银河通用, Zhiyuan/智元, TARS/它石智航), AI infrastructure (MicroNano Core/微纳核芯 compute-in-memory chips, Lingchu Smart/灵初智能), enterprise AI agents (Yoolee AI/元理智能), and adjacent frontier areas (low-altitude economy via Zero Gravity Aircraft/零重力).
Revenue is generated through standard VC mechanics—management fees on committed capital and carried interest from exits—with no disclosed revenue figures. The firm has built a "BlueRun Family" (蓝驰家族) post-investment platform including the Booming Hub event series (expanding from Beijing to Tokyo in 2025) and Hong Kong government co-programs, formalized a strategic relationship with Hong Kong Investment Corporation (HKIC) via portfolio company Galbot, and brokered a 2025 Eli Lilly strategic partnership for portfolio company LTZ Therapeutics. The firm is private, China-domiciled, and independently owned with no parent company.
BlueRun Ventures firmographics
Firmographics- Name
- BlueRun Ventures
- Legal name
- 蓝驰创投
- Website
- https://lanchivc.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Short description
- BlueRun Ventures (蓝驰创投) is a Beijing-headquartered early-stage venture capital firm managing 15B+ RMB across 200+ Chinese technology, consumer, and healthcare startups, with deep recent focus on AI and embodied intelligence including Moonshot AI, Zhiyuan Robotics, and Galbot.
- Ownership category
- akta.pro rank
BlueRun Ventures industry classification
Industry- Product category
- Early-stage venture capital investment
- NAICS
- Other Financial Vehicles (52599)
- SIC
- Investment Advice (6282)
- akta.pro industry
- Early-Stage Venture Capital (Series A/B)Sector-Focused Venture Capital (Vertical Specialists)Business Services (B2B) Growth Equity
Keywords
Where BlueRun Ventures is headquartered
LocationHeadquarters
- HQ city
- Chaoyang
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
BlueRun Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- 基金管理费收入: 作为早期创业投资基金,蓝驰创投通过管理费和管理业绩提成(Carried Interest)获取收入
- 投资组合回报: 通过投资于早期创业公司并在后续融资中退出获取投资回报,包括理想汽车、水滴公司、青云科技、怪兽充电等成功上市案例
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
BlueRun Ventures product offering
Product offeringCore offering
BlueRun Ventures is an early-stage venture capital firm that invests patient capital into technology startups across AI, embodied intelligence, hard tech, consumer tech, and biotech in China. It supports founders from seed through growth stages with capital, industry resources, and post-investment services through the "BlueRun Family" platform. Revenue is generated through fund management fees and carried interest on long-cycle venture funds.
Product overview
BlueRun Ventures is a venture capital firm that has been operating in China for 20 years, managing over 150 billion RMB in long-cycle capital. The firm has invested in over 200 startup companies across technology, consumer, and healthcare sectors. BlueRun Ventures does not develop or sell technology products or services; it is an investment firm that provides capital and support to early-stage startups.
Differentiator
Problem solved
Functional benefit
Products and services
- Early-stage venture capital investment (seed, angel, Series A and beyond) Equity investment in early-stage (Series A and earlier) Chinese technology startups, with 80% of investments led by BlueRun; covers AI, embodied intelligence, hard tech, consumer tech, and innovative healthcare/biotech.
- BlueRun Family post-investment support service system (蓝驰家族投后服务体系) Post-investment value-add services for portfolio companies, including industry matchmaking, financing support, policy/government advisory, and ecosystem events. Available to companies that have received BlueRun investment.
- Booming Hub industry events and community program BlueRun-hosted industry summits and conferences that bring together founders, portfolio companies, and industry partners for deal sourcing, ecosystem building, and thematic discussions.
Quantifiable outcome
- 2024年度最佳早期创业投资机构TOP2
- +2 more outcomes
Companies that use BlueRun Ventures
Customer profileNamed customers16 records
Segments3 records
Ideal customer profiles2 records
BlueRun Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
BlueRun Ventures partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- 礼来Eli Lillycore泽安生物医药与礼来达成战略合作,开发髓系细胞衔接器药物治疗自身免疫性疾病
- 香港特区政府投资推广署core共同举办「科创企业如何把握香港政策机遇」圆桌交流会,帮助被投企业对接香港资源
Scale indicators15 records
Recent moves6 records
Expansion highlights5 records
BlueRun Ventures competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
BlueRun Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
BlueRun Ventures leadership team
Management profileNumber of profiles
Profiles4 records
BlueRun Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BlueRun Ventures M&A and investment
M&A and investmentM&A
Investments62 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BlueRun Ventures
What does BlueRun Ventures do?
BlueRun Ventures is an early-stage venture capital firm that invests patient capital into technology startups across AI, embodied intelligence, hard tech, consumer tech, and biotech in China. It supports founders from seed through growth stages with capital, industry resources, and post-investment services through the "BlueRun Family" platform. Revenue is generated through fund management fees and carried interest on long-cycle venture funds.
Is BlueRun Ventures a public or private company?
BlueRun Ventures is a private company. It is classified as management employee owned and is currently operating.
When was BlueRun Ventures founded?
BlueRun Ventures was founded in 2005.
Where is BlueRun Ventures based?
BlueRun Ventures is headquartered in Chaoyang, China, in the Asia region.
How does BlueRun Ventures make money?
Two revenue lines are on record. 基金管理费收入 is the primary driver. The others are 投资组合回报.
Does BlueRun Ventures have an API?
No public API is recorded for BlueRun Ventures.
What industry is BlueRun Ventures in?
BlueRun Ventures's product category is Early-stage venture capital investment. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52599 and its SIC code is 6282.